|
1
|
Salinas CA, Tsodikov A, Ishak-Howard M and
Cooney KA: Prostate cancer in young men: An important clinical
entity. Nat Rev Urol. 11:317–323. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tabayoyong W and Abouassaly R: Prostate
Cancer Screening and the Associated Controversy. Surg Clin North
Am. 95:1023–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Etzioni R, Tsodikov A, Mariotto A, Szabo
A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson
DF, et al: Quantifying the role of PSA screening in the US prostate
cancer mortality decline. Cancer Causes Control. 19:175–181. 2008.
View Article : Google Scholar
|
|
6
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kontos CK, Adamopoulos PG and Scorilas A:
Prognostic and predictive biomarkers in prostate cancer. Expert Rev
Mol Diagn. 15:1567–1576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dimakakos A, Armakolas A and Koutsilieris
M: Novel tools for prostate cancer prognosis, diagnosis, and
follow-up. BioMed Res Int. 2014:8906972014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thalgott M, Rack B, Maurer T, Souvatzoglou
M, Eiber M, Kress V, Heck MM, Andergassen U, Nawroth R, Gschwend
JE, et al: Detection of circulating tumor cells in different stages
of prostate cancer. J Cancer Res Clin Oncol. 139:755–763. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hessels D and Schalken JA: Urinary
biomarkers for prostate cancer: A review. Asian J Androl.
15:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wagner SD and Berglund JA: Alternative
pre-mRNA splicing. Methods Mol Biol. 1126:45–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelemen O, Convertini P, Zhang Z, Wen Y,
Shen M, Falaleeva M and Stamm S: Function of alternative splicing.
Gene. 514:1–30. 2013. View Article : Google Scholar
|
|
13
|
Krause WC, Shafi AA, Nakka M and Weigel
NL: Androgen receptor and its splice variant, AR-V7, differentially
regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int
J Biochem Cell Biol. 54:49–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lapuk AV, Volik SV, Wang Y and Collins CC:
The role of mRNA splicing in prostate cancer. Asian J Androl.
16:515–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu LL, Xie N, Sun S, Plymate S, Mostaghel
E and Dong X: Mechanisms of the androgen receptor splicing in
prostate cancer cells. Oncogene. 33:3140–3150. 2014. View Article : Google Scholar
|
|
16
|
Sprenger CC and Plymate SR: The link
between androgen receptor splice variants and castration-resistant
prostate cancer. Horm Cancer. 5:207–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Omenn GS, Menon R and Zhang Y: Innovations
in proteomic profiling of cancers: Alternative splice variants as a
new class of cancer biomarker candidates and bridging of proteomics
with structural biology. J Proteomics. 90:28–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z
and He J: Prognostic alternative mRNA splicing signature in
non-small cell lung cancer. Cancer Lett. 393:40–51. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ryan MC, Cleland J, Kim R, Wong WC and
Weinstein JN: SpliceSeq: A resource for analysis and visualization
of RNA-Seq data on alternative splicing and its functional impacts.
Bioinformatics. 28:2385–2387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sveen A, Kilpinen S, Ruusulehto A, Lothe
RA and Skotheim RI: Aberrant RNA splicing in cancer; expression
changes and driver mutations of splicing factor genes. Oncogene.
35:2413–2427. 2016. View Article : Google Scholar
|
|
21
|
Yoshida K and Ogawa S: Splicing factor
mutations and cancer. Wiley Interdiscip Rev RNA. 5:445–459. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogawa S: Splicing factor mutations in
myelodysplasia. Int J Hematol. 96:438–442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Silipo M, Gautrey H and Tyson-Capper A:
Deregulation of splicing factors and breast cancer development. J
Mol Cell Biol. 7:388–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karni R, de Stanchina E, Lowe SW, Sinha R,
Mu D and Krainer AR: The gene encoding the splicing factor SF2/ASF
is a proto-oncogene. Nat Struct Mol Biol. 14:185–193. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adler AS, McCleland ML, Yee S, Yaylaoglu
M, Hussain S, Cosino E, Quinones G, Modrusan Z, Seshagiri S, Torres
E, et al: An integrative analysis of colon cancer identifies an
essential function for PRPF6 in tumor growth. Genes Dev.
28:1068–1084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ryan M, Wong WC, Brown R, Akbani R, Su X,
Broom B, Melott J and Weinstein J: TCGASpliceSeq a compendium of
alternative mRNA splicing in cancer. Nucleic Acids Res.
44:D1018–D1022. 2016. View Article : Google Scholar :
|
|
27
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Piva F, Giulietti M, Burini AB and
Principato G: SpliceAid 2: A database of human splicing factors
expression data and RNA target motifs. Hum Mutat. 33:81–85. 2012.
View Article : Google Scholar
|
|
29
|
Lex A, Gehlenborg N, Strobelt H, Vuillemot
R and Pfister H: UpSet: Visualization of intersecting sets. IEEE
Trans Vis Comput Graph. 20:1983–1992. 2014. View Article : Google Scholar
|
|
30
|
Fredericks AM, Cygan KJ, Brown BA and
Fairbrother WG: RNA-Binding Proteins: Splicing Factors and Disease.
Biomolecules. 5:893–909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M,
Tindall DJ, Lim B, Zhu R, Wang L, et al: Androgen receptor splice
variants bind to constitutively open chromatin and promote
abiraterone-resistant growth of prostate cancer. Nucleic Acids Res.
46:1895–1911. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Munkley J, Livermore K, Rajan P and
Elliott DJ: RNA splicing and splicing regulator changes in prostate
cancer pathology. Hum Genet. 136:1143–1154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ciccarese C, Santoni M, Brunelli M, Buti
S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R,
Tortora G, et al: AR-V7 and prostate cancer: The watershed for
treatment selection? Cancer Treat Rev. 43:27–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Couture F, Sabbagh R, Kwiatkowska A,
Desjardins R, Guay SP, Bouchard L and Day R: PACE4 Undergoes an
Oncogenic Alternative Splicing Switch in Cancer. Cancer Res.
77:6863–6879. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hernandez JR, Kim JJ, Verdone JE, Liu X,
Torga G, Pienta KJ and Mooney SM: Alternative CD44 splicing
identifies epithelial prostate cancer cells from the mesenchymal
counterparts. Med Oncol. 32:1592015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cappellari M, Bielli P, Paronetto MP,
Ciccosanti F, Fimia GM, Saarikettu J, Silvennoinen O and Sette C:
The transcriptional co-activator SND1 is a novel regulator of
alternative splicing in prostate cancer cells. Oncogene.
33:3794–3802. 2014. View Article : Google Scholar
|
|
37
|
Robert C and Watson M: The incredible
complexity of RNA splicing. Genome Biol. 17:2652016. View Article : Google Scholar
|
|
38
|
Brasky TM, Darke AK, Song X, Tangen CM,
Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM,
Parnes HL, et al: Plasma phospholipid fatty acids and prostate
cancer risk in the SELECT trial. J Natl Cancer Inst. 105:1132–1141.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bassett JK, Severi G, Hodge AM, MacInnis
RJ, Gibson RA, Hopper JL, English DR and Giles GG: Plasma
phospholipid fatty acids, dietary fatty acids and prostate cancer
risk. Int J Cancer. 133:1882–1891. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Moreel X, Allaire J, Léger C, Caron A,
Labonté MÈ, Lamarche B, Julien P, Desmeules P, Têtu B and Fradet V:
Prostatic and dietary omega-3 fatty acids and prostate cancer
progression during active surveillance. Cancer Prev Res (Phila).
7:766–776. 2014. View Article : Google Scholar
|
|
41
|
Gang X, Yang Y, Zhong J, Jiang K, Pan Y,
Karnes RJ, Zhang J, Xu W, Wang G and Huang H: P300
acetyltransferase regulates fatty acid synthase expression, lipid
metabolism and prostate cancer growth. Oncotarget. 7:15135–15149.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiao D, Powolny AA, Moura MB, Kelley EE,
Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B and Singh
SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to
trigger reactive oxygen species-mediated death of human prostate
cancer cells. J Biol Chem. 285:26558–26569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen ZP, Li M, Zhang LJ, He JY, Wu L, Xiao
YY, Duan JA, Cai T and Li WD: Mitochondria-targeted drug delivery
system for cancer treatment. J Drug Target. 24:492–502. 2016.
View Article : Google Scholar
|
|
44
|
Goltz D, Gevensleben H, Dietrich J,
Ellinger J, Landsberg J, Kristiansen G and Dietrich D: Promoter
methylation of the immune checkpoint receptor PD-1 (PDCD1) is an
independent prognostic biomarker for biochemical recurrence-free
survival in prostate cancer patients following radical
prostatectomy. OncoImmunology. 5:e12215552016. View Article : Google Scholar :
|
|
45
|
Holmes EE, Goltz D, Sailer V, Jung M,
Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G,
et al: PITX3 promoter methylation is a prognostic biomarker for
biochemical recurrence-free survival in prostate cancer patients
after radical prostatectomy. Clin Epigenetics. 8:1042016.
View Article : Google Scholar :
|
|
46
|
Meller S, Zipfel L, Gevensleben H,
Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M,
Kristiansen G, et al: CDO1 promoter methylation is associated with
gene silencing and is a prognostic biomarker for biochemical
recurrence-free survival in prostate cancer patients. Epigenetics.
11:871–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gonzàlez-Porta M, Frankish A, Rung J,
Harrow J and Brazma A: Transcriptome analysis of human tissues and
cell lines reveals one dominant transcript per gene. Genome Biol.
14:R702013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Soussi T, Leroy B and Taschner PE:
Recommendations for analyzing and reporting TP53 gene variants in
the high-throughput sequencing era. Hum Mutat. 35:766–778. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Thadani-Mulero M, Portella L, Sun S, Sung
M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR and
Giannakakou P: Androgen receptor splice variants determine taxane
sensitivity in prostate cancer. Cancer Res. 74:2270–2282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Carstens RP, Eaton JV, Krigman HR, Walther
PJ and Garcia-Blanco MA: Alternative splicing of fibroblast growth
factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene.
15:3059–3065. 1997. View Article : Google Scholar
|
|
51
|
Anczuków O and Krainer AR: Splicing-factor
alterations in cancers. RNA. 22:1285–1301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee Y and Rio DC: Mechanisms and
regulation of alternative Pre-mRNA splicing. Annu Rev Biochem.
84:291–323. 2015. View Article : Google Scholar : PubMed/NCBI
|
